137 related articles for article (PubMed ID: 37150813)
21. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
22. New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.
Genovese G; Di Zenzo G; Cozzani E; Berti E; Cugno M; Marzano AV
Front Immunol; 2019; 10():1506. PubMed ID: 31312206
[TBL] [Abstract][Full Text] [Related]
23. Proinflammatory role of blister fluid-derived exosomes in bullous pemphigoid.
Fang H; Shao S; Jiang M; Dang E; Shen S; Zhang J; Qiao P; Li C; Wang G
J Pathol; 2018 May; 245(1):114-125. PubMed ID: 29468680
[TBL] [Abstract][Full Text] [Related]
24. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
[TBL] [Abstract][Full Text] [Related]
25. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.
Teraki Y; Hotta T; Shiohara T
J Invest Dermatol; 2001 Nov; 117(5):1097-102. PubMed ID: 11710918
[TBL] [Abstract][Full Text] [Related]
26. Adaptive and innate immune pathogenesis of bullous pemphigoid: A review.
Yan T; Zhang Z
Front Immunol; 2023; 14():1144429. PubMed ID: 36993969
[TBL] [Abstract][Full Text] [Related]
27. Role of different pathways of the complement cascade in experimental bullous pemphigoid.
Nelson KC; Zhao M; Schroeder PR; Li N; Wetsel RA; Diaz LA; Liu Z
J Clin Invest; 2006 Nov; 116(11):2892-900. PubMed ID: 17024247
[TBL] [Abstract][Full Text] [Related]
28. The role of T cells in pemphigus vulgaris and bullous pemphigoid.
Fang H; Li Q; Wang G
Autoimmun Rev; 2020 Nov; 19(11):102661. PubMed ID: 32942041
[TBL] [Abstract][Full Text] [Related]
29. Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease.
Margaroli C; Bradley B; Thompson C; Brown MR; Giacalone VD; Bhatt L; Stoff B; Ahuja S; Springman E; Tirouvanziam R; Feldman RJ
Exp Dermatol; 2020 Dec; 29(12):1191-1198. PubMed ID: 33047366
[TBL] [Abstract][Full Text] [Related]
30. Localized bullous pemphigoid: report of a case with an immunofluorescence and electron microscopical studies on the lesional distribution of 180-KD bullous pemphigoid antigen, beta 4 integrin, and type VII collagen.
Kitajima Y; Suzuki M; Johkura Y; Yaoita H
J Dermatol; 1993 Jul; 20(7):406-12. PubMed ID: 8408921
[TBL] [Abstract][Full Text] [Related]
31. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid.
Kakinuma T; Wakugawa M; Nakamura K; Hino H; Matsushima K; Tamaki K
Br J Dermatol; 2003 Feb; 148(2):203-10. PubMed ID: 12588369
[TBL] [Abstract][Full Text] [Related]
32. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen.
Ståhle-Bäckdahl M; Inoue M; Guidice GJ; Parks WC
J Clin Invest; 1994 May; 93(5):2022-30. PubMed ID: 8182134
[TBL] [Abstract][Full Text] [Related]
33. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
34. Role of cell-mediated immune reaction in blister formation of bullous pemphigoid.
Kaneko F; Minagawa T; Takiguchi Y; Suzuki M; Itoh N
Dermatology; 1992; 184(1):34-9. PubMed ID: 1558993
[TBL] [Abstract][Full Text] [Related]
35. Gene Expression Profiling Suggests that Complement Activation Is Important for Blister Formation in Bullous Pemphigoid.
Lamberts A; Kotnik N; Meijer JM; van Kempen LC; Diercks GFH; Horváth B
J Invest Dermatol; 2023 Aug; 143(8):1591-1594.e2. PubMed ID: 36863446
[No Abstract] [Full Text] [Related]
36. Dual role of basophils in the pathogenesis of bullous pemphigoid elucidated by pathological and ultrastructural studies.
Kimura R; Sugita K; Horie T; Yamamoto O
Eur J Dermatol; 2022 May; 32(3):322-333. PubMed ID: 36065540
[TBL] [Abstract][Full Text] [Related]
37. T cells in bullous pemphigoid. Presence of activated CD4+ T cells at the basement membrane zone in pre- and peri-bullous skin.
Michalaki H; Nicolas JF; Kanitakis J; Machado P; Roche P; Thivolet J
Reg Immunol; 1990-1991; 3(3):151-5. PubMed ID: 1982989
[TBL] [Abstract][Full Text] [Related]
38. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
39. Internalization of the 180 kDa bullous pemphigoid antigen as immune complexes in basal keratinocytes: an important early event in blister formation in bullous pemphigoid.
Kitajima Y; Nojiri M; Yamada T; Hirako Y; Owaribe K
Br J Dermatol; 1998 Jan; 138(1):71-6. PubMed ID: 9536225
[TBL] [Abstract][Full Text] [Related]
40. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid.
Yamamoto K; Inoue N; Masuda R; Fujimori A; Saito T; Imajoh-Ohmi S; Shinkai H; Sakiyama H
J Invest Dermatol; 2002 Mar; 118(3):485-92. PubMed ID: 11874488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
